Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Cramer 5-marker panel for ovarian cancer

Cramer 5-marker panel for ovarian cancer



QA State: Curated
Short Name:
HGNC Name:

The PLCO phase III specimens (test half) revealed marker panels produced only marginal improvement over CA 125 alone and, in some case, worse performance. Besides searching for new markers, some ways to improve detection might include: 1) Add epidemiologic variables, and 2) Add in prior markers values.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


The PLCO accepted the phase II reports (SPORE/EDRN/PLCO Ovarian Validation Study) and sent identical sets to the assay sites. Each set included sera for cases most proximate to the diagnosis of ovarian cancer which (on average) was about 9 months prior. There were 951 controls matched by age and timing of specimen collection including 475 general population controls, 238 with false positive CA 125, and 238 with family history of breast or ovarian cancer. 90 quality control specimens were also included. Investigators tested their markers and marker panels blinded to the status of the cases. PLCO unblinded the data in stages to allow further algorithm development.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated publications found.


No associated resources found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.